Research
Hormonal
Tirzepatide mitigates ischemic stroke damage by restoring Blood-Brain Barrier (BBB) integrity via Claudin-1 expression and reducing neuroinflammation.
This finding is currently limited to animal studies. While promising for stroke recovery, it does not yet translate to a standard human treatment protocol for acute stroke.
LimitedSupportsLOW confidence
O tratamento com TRZ em camundongos MCAO resultou em melhora significativa nas pontuações neurológicas e mitigou o dano neuronal. Isso foi alcançado pela redução do volume de infarto e, crucialmente, pela melhora da disfunção da BHE (Wang et al., 2025).
Why this rating
Based on a single pre-clinical animal study (Wang et al., 2025) cited in the review.
Source
EFEITOS NEUROPROTETORES DA SEMAGLUTIDA E TIRZEPATIDA DURANTE TRATAMENTO DE OBESIDADE E DIABETES MELLITUS TIPO 2
Alyson Oliveira Mergulhão et al. · Aracê. · 2025
DOI 10.56238/arev7n11-226
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →